Islay Capital Management LLC Makes New $867,000 Investment in Elevance Health, Inc. $ELV

Islay Capital Management LLC acquired a new position in shares of Elevance Health, Inc. (NYSE:ELV) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,472 shares of the company’s stock, valued at approximately $867,000.

Other hedge funds have also modified their holdings of the company. Rossby Financial LCC increased its holdings in Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after purchasing an additional 44 shares during the period. J.Safra Asset Management Corp acquired a new position in shares of Elevance Health during the fourth quarter worth about $32,000. ORG Partners LLC increased its stake in shares of Elevance Health by 120.4% during the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after buying an additional 59 shares during the period. Dorato Capital Management acquired a new stake in Elevance Health in the fourth quarter valued at approximately $41,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in Elevance Health in the fourth quarter valued at approximately $38,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Trading Down 0.7%

Shares of Elevance Health stock opened at $401.19 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. The company has a market capitalization of $87.12 billion, a P/E ratio of 17.06, a PEG ratio of 2.29 and a beta of 0.67. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $426.98. The company’s fifty day moving average is $368.63 and its two-hundred day moving average is $345.42.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same period in the prior year, the company earned $11.97 earnings per share. The business’s revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Analysts forecast that Elevance Health, Inc. will post 26.93 earnings per share for the current year.

Elevance Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a $1.72 dividend. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. Elevance Health’s payout ratio is presently 29.26%.

Insider Activity

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the transaction, the director directly owned 10,734 shares of the company’s stock, valued at $4,312,599.18. This represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.34% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

ELV has been the subject of several analyst reports. Truist Financial boosted their price target on shares of Elevance Health from $375.00 to $450.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Leerink Partners set a $364.00 price objective on shares of Elevance Health in a research report on Thursday, April 23rd. Evercore reiterated a “hold” rating on shares of Elevance Health in a research note on Tuesday, May 19th. Deutsche Bank Aktiengesellschaft raised Elevance Health from a “hold” rating to a “buy” rating and increased their target price for the company from $363.00 to $498.00 in a report on Wednesday, May 20th. Finally, Citigroup raised Elevance Health to a “buy” rating in a report on Wednesday, April 29th. Fourteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, Elevance Health has a consensus rating of “Moderate Buy” and a consensus target price of $416.11.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.